Therapeutic effects of rhu-TNFR-Fc on adjuvant arthritis and its possible mechanism in rats

于扬,黄梅,李卫东,林志彬
DOI: https://doi.org/10.3321/j.issn:1001-2494.2004.06.012
2004-01-01
Abstract:OBJECTIVE: To study the therapeutic effects of rhu-TNFR-Fc on AA and its possible mechanism in rats. METHODS: Wistar rats were immunized with Freund's complete adjuvant and treated with rhu-TNFR-Fc from day 12 to 23 after adjuvant injection. The negative control rats received sterile saline and the positive control group received Dexamethasone. The secondary paw swelling and arthritis index were examined on day 12, 15, 17, 19, 21, 23, 25 and 27 after adjuvant injection. At the termination of the trial (day 28), the content of NO secreted by macrophage in the presence of LPS was assessed and T cell subpopulation in rats were measured by flowing cytometry. ELISA assays were performed to determine serum IL-1β and TNF-α. The activity of TNF-α in the culture supernatant was also measured using L929 cell line or ELISA assays in vitro. RESULTS: rhu-TNFR-Fc (0.44, 0.88, 1.75 mg′kg -1) subcutaneous injection (s.c) significantly inhibited secondary inflammatory reactions(inflammatory swelling and multiple arthritis) in AA rats. Serum IL-1β and NO level were significantly reduced. There was no significant variation in the CD4 +/CD8 + ratio. rhu-TNFR-Fc (0.175 - 87.5 μg·mL -1 inhibited the activity of TNF-α in the culture supernatant in vitro. But no difference was observed with ELISA assays. CONCLUSION: The results suggested that rhu-TNFR-Fc may have antiarthritic properties in this experimental model and the mechanisms may be that neutralization of TNF-α reduces the release of cytokines such as IL-1β and other inflammatory mediators such as NO.
What problem does this paper attempt to address?